Bubela, Tania
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Tania Bubela
Bubela, Tania Marjorie.
VIAF ID: 250000856 (Personal)
Permalink: http://viaf.org/viaf/250000856
Preferred Forms
-
100 1 _
‡a
Bubela, Tania
-
100 1 _ ‡a Bubela, Tania
-
100 1 _ ‡a Bubela, Tania
-
100 1 _ ‡a Bubela, Tania
-
100 1 _ ‡a Bubela, Tania
-
100 1 _ ‡a Bubela, Tania
-
100 1 _
‡a
Bubela, Tania
-
100 1 _
‡a
Bubela, Tania Marjorie
-
100 1 _ ‡a Bubela, Tania Marjorie (sparse)
-
100 1 _ ‡a Bubela, Tania Marjorie.
-
100 0 _
‡a
Tania Bubela
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| AMP v. Myriad: A Surgical Strike on Blockbuster Business Models |
|
| Application of protection motivation theory to clinical trial enrolment for pediatric chronic conditions |
|
| Author name disambiguation for collaboration network analysis and visualization |
|
| Automated content analysis as a tool for research and practice: a case illustration from the Prairie Creek and Nico environmental assessments in the Northwest Territories, Canada |
|
| Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. |
|
| Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research |
|
| Cell therapy licensing: a web for the unwary in Kimble v. Marvel Entertainment? |
|
| Challenges for intellectual property management of HIV vaccine-related research and development: part 2, the Canadian context |
|
| Choroideremia research: Report and perspectives on the second international scientific symposium for choroideremia |
|
| Circumpolar stakeholder perspectives on Geographic Information Systems for communicating the health impacts of development |
|
| Commercialization and collaboration: competing policies in publicly funded stem cell research? |
|
| Communicating the promise for ocular gene therapies: challenges and recommendations. |
|
| Creating a data resource: what will it take to build a medical information commons? |
|
| Current practices and reform proposals for the regulation of advanced medicinal products in Canada |
|
| DNA barcoding in the media: does coverage of cool science reflect its social context? |
|
| Do the print media "hype" genetic research? A comparison of newspaper stories and peer-reviewed research papers |
|
| Drugs: Regulate 'home-brew' opiates |
|
| Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation |
|
| The ethics of genome editing in the clinic: A dose of realism for healthcare leaders. |
|
| Factors affecting the trappability of red foxes in Kosciusko National Park |
|
| Fostering reproducibility in industry-academia research |
|
| Gene patents—more evidence needed, but policymakers must act |
|
| Genetic resources and traditional knowledge : case studies and conflicting interests |
|
| The global landscape of stem cell clinical trials |
|
| Governance of a global genetic resource commons for non-commercial research: A case-study of the DNA barcode commons |
|
| Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol |
|
| "If they tell me to get it, I'll get it. If they don't...": Immunization decision-making processes of immigrant mothers. |
|
| Implementing Socially Responsible Licensing for Global Health: Beyond Neglected Diseases |
|
| Importance of Participant-Centricity and Trust for a Sustainable Medical Information Commons |
|
| "Is a cure in my sight?" Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials |
|
| Is belief larger than fact: expectations, optimism and reality for translational stem cell research |
|
| Keeping score, strengthening policy and fighting bad actors over access to research tools. |
|
| Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. |
|
| Legal agreements and the governance of research commons: lessons from materials sharing in mouse genomics |
|
| L'éthique de la modification du génome en clinique : une dose de réalisme pour les leaders en santé. |
|
| Lost in translation: the Canadian access to medicines regime from transnational activism to domestic implementation. |
|
| Media portrayal of conflicts of interest in herbal remedy clinical trials. |
|
| Medical Information Commons to Support Learning Healthcare Systems: Examples From Canada |
|
| Monitoring progress toward United Nations commitments: characteristics of Canadian legislation to promote tobacco control, physical activity and healthy eating. A descriptive study |
|
| More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies? |
|
| The mouse that trolled (again). |
|
| Myriad and the mass media: the covering of a gene patent controversy |
|
| The new age of the Nagoya Protocol |
|
| Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process |
|
| Ocular gene transfer in the spotlight: implications of newspaper content for clinical communications |
|
| Participant perspectives on a phase I/II ocular gene therapy trial (NCT02077361) |
|
| Patent landscaping for life sciences innovation: toward consistent and transparent practices |
|
| Patents and misplaced angst: lessons for translational stem cell research from genomics |
|
| Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. |
|
| Post-publication sharing of data and tools |
|
| Prospects for scaling-up supervised injection facilities in Canada: the role of evidence in legal and political decision-making |
|
| Provenance and risk in transfer of biological materials |
|
| Recalibrating intellectual property rights to enhance translational research collaborations |
|
| Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada |
|
| Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate |
|
| Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data. |
|
| Role and reality: technology transfer at Canadian universities |
|
| Science communication reconsidered |
|
| Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment |
|
| The stem cell research environment: a patchwork of patchworks |
|
| Stem cells, politics and the progress paradigm |
|
| Stepping Into and Out of the Void: Funding Dynamics of Human Embryonic Stem Cell Research in California, Sweden, and South Korea |
|
| Sustaining large-scale infrastructure to promote pre-competitive biomedical research: lessons from mouse genomics. |
|
| Synthetic biology confronts publics and policy makers: challenges for communication, regulation and commercialization. |
|
| Use and misuse of material transfer agreements: lessons in proportionality from research, repositories, and litigation |
|
| Value-engineered translation: developing biotherapeutics that align with health-system needs |
|
| When pictures waste a thousand words: analysis of the 2009 H1N1 pandemic on television news |
|
| Why a criminal ban? Analyzing the arguments against somatic cell nuclear transfer in the Canadian parliamentary debate |
|
